Retinitis pigmentosa (RP) is a group of inherited conditions in which the light-sensing cells of the retina slowly stop working. Night vision is often the first thing to go. One of the more severe forms is X-linked RP caused by changes in the RPGR gene, which mostly affects boys and men. A gene therapy for this form, laruparetigene zovaparvovec (laru-zova), has now met the main goal of a pivotal trial, according to topline results announced by its developer, Beacon Therapeutics.
About the VISTA trial
VISTA was a randomized, controlled phase 2/3 study of 85 males aged 12 to 48 with RPGR-related X-linked RP. Participants received a high or low dose of the therapy, delivered by surgery under the retina, or were assigned to an untreated control group. All were followed for 12 months.
What was reported
- The main measure was a gain of 15 letters or more in low-luminance visual acuity, a test of seeing in dim light.
- 31.0% of the high-dose group and 24.1% of the low-dose group reached that level; no one in the control group did.
- At a 10-letter threshold, responder rates were 48.3% (high dose), 58.6% (low dose), and 3.7% (control).
- Most eye side effects were mild to moderate and largely linked to the surgery itself. Two serious eye events, both attributed to the procedure, occurred in the low-dose group.
Important context
These are topline results from the company, not yet a full peer-reviewed publication. The therapy is not FDA approved; Beacon says it plans a rolling Biologics License Application later in 2026. Another RPGR gene therapy from a different company did not meet its main goal in 2025, which shows how much the choice of outcome measure matters in this field. And this treatment applies only to one genetic cause of RP.
If you or a family member has RP
- Ask about genetic testing. Knowing the exact gene determines which trials or treatments may apply.
- Inherited retinal disease is managed by retina and genetics specialists; ask your eye doctor for a referral.
- Low-vision services can help with lighting, mobility, and reading now, while research continues.
For more plain-language eye-health reading, see epilasikmd.com.
Source: Laru-zova meets primary endpoint in pivotal VISTA trial for X-linked retinitis pigmentosa (Ophthalmology Times, 09/22/2026). This article is an educational summary written by Khanna Vision Institute and is not a substitute for medical advice.